The impact of Hashimoto’s thyroiditis on the diagnostic utility of P63 and CK19 immunohistochemistry markers in predicting thyroid cancer
DOI:
https://doi.org/10.18203/2349-2902.isj20243544Keywords:
CK19, Hashimoto’s thyroiditis, Immunohistochemistry markers, p63, Thyroid cancerAbstract
Background: The incidence of thyroid cancer (TC) and Hashimoto’s thyroiditis (HT) is increasing worldwide. Coexisting HT adds to diagnostic confusion in establishing TC on histopathological examination (HPE). Studies have shown the promising role of immunohistochemistry markers in predicting cancer, but the impact of coexisting HT is unclear. This prospective study determined the impact of HT on the diagnostic utility of p63 and CK19 in predicting thyroid cancer.
Methods: Out of 103 patients undergoing total thyroidectomy for benign or malignant thyroid nodules, 31 patients (mean age=39.7 years, Male:Female=4:27) with elevated thyroid autoantibodies were studied. HPE of formalin-fixed paraffin-embedded tissue from surgical specimens confirmed the final diagnosis. Sections 2-4μ were stained for immunohistochemistry using the standard avidin-biotin complex method with antibodies against P63 and CK19. Expression in 10% or more of neoplastic cells qualified as positive while expression in less than 10% was considered negative. Receiver Operating Characteristic (ROC) assessed the diagnostic accuracy.
Results: Histopathology comprised 58.1% benign and 41.9% malignant lesions. CK19 exhibited membranous expression in 87.1%, while p63 exhibited focal nuclear expression in 35.5% of cases. In ROC analysis predicting TC for entire cohort, the area under curve (AUC) of P63 was 0.6 and CK19 was 0.532. In subgroup with HT, the AUC of p63 was 0.8. Each P>0.05.
Conclusions: P63 expression had better predictability for thyroid cancer with co-existent Hashimoto’s thyroiditis but was not statistically significant. Whereas, CK19 was non-specific and unreliable. Histomorphological features on HPE are the gold standard for diagnostic decisions.
References
Hu X, Chen Y, Shen Y, Tian R, Sheng Y, et al. Global prevalence and epidemiological trends of Hashimoto’s thyroiditis in adults: A systematic review and meta-analysis. Front Public Health. 2022;13;10.
Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021;9(4):225–34.
James BC, Mitchell JM, Jeon HD, Vasilottos N, Grogan RH, Aschebrook-Kilfoy B. An update in international trends in incidence rates of thyroid cancer, 1973–2007. Cancer Causes and Control. 2018;29(4–5):465-73.
la Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: A global overview. Int J Cancer. 2015;1;136(9):2187–95.
Jankovic B, Le KT, Hershman JM. Hashimoto’s thyroiditis and papillary thyroid carcinoma: Is there a correlation. J Clin Endocrinol Metabol. 2013;98:474–82.
Sekkath Veedu J, Wang K, Lei F, Chen Q, Huang B, Mathew A. Trends in thyroid cancer incidence in India. J Clin Oncol. 2018;36(15):246-9.
Karunakaran P, Tamilselvan N, Thenmozhi. Rising trend in thyroid cancer – a truth or myth? – a prospective study in a tertiary care hospital in Southern India. IOSR. 2016;15(9):45–8.
Karunakaran P, Devadas G. Histopathological pattern of thyroid diseases and its correlation with post-thyroidectomy hypocalcemia: a prospective study in iodine-sufficient Southern India. Int Surg J. 2020;23;7(11):3749–54.
El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol. 2008;3(1):5.
Al-Zughaibi IFA, Kamal MS. The Part Immunohistochemical Markers (CK19 AND CD56) Play in Distinguishing Papillary Thyroid Carcinoma from Other Pathological Imitators. Egypt J Hosp Med. 2023;1;90(2):3495–500.
Berho M, Suster S. Clear nuclear changes in Hashimoto’s thyroiditis. A clinicopathologic study of 12 cases. Ann Clin Lab Sci. 1995;25(6):513–21.
Bai Y, Kakudo K, Jung CK. Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification. Endocrinology and Metabolism. 2020;31;35(4):696–715.
Hanege FM, Tuysuz O, Celik S, Sakallıoglu O, Arslan Solmaz O. Hashimoto’s thyroiditis in papillary thyroid carcinoma: a 22-year study. Acta Otorhinolaryngologica Italica. 2021;41(2):142–5.
Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT. Hashimoto’s thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology. 2004;45(1):39–46.
Alshenawy HA. Utility of Immunohistochemical Markers in Diagnosis of Follicular Cell Derived Thyroid Lesions. Pathology & Oncology Research. 2014;23;20(4):819–28.
Abouhashem NS, Talaat SM. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Pathol Res Pract. 2017;1(5):509–17.
Manzella L, Stella S, Pennisi MS, Tirrò E, Massimino M, Romano C, et al. New insights in thyroid cancer and p53 family proteins. Int J Molec Sci. 2017;18:1325.
Divani SN, Kalodimos GP, Lioupis MA, Syrmos NC. Hashimoto’s thyroiditis and papillary thyroid carcinoma. Are cytokeratin 19 and P63 proteins of any diagnostic value? Hell J Nucl Med. 2016;19(3):250–3.
Preto A, Reis-Filho JS, Ricardo S, Soares P. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. Pathol Res Pract. 2002;198(7):449–54.
Tan A, Etit D, Bayol U, Altinel D, Tan S. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol. 2011;15(2):108–16.
Radu TG, Mogoantă L, Busuioc CJ, StĂnescu C, Grosu F. Histological and immunohistochemical aspects of papillary thyroid cancer. Romanian J of Morph and Embryol. 2015;56(2):46-9.
Moon S, Chung HS, Yu JM, Yoo HJ, Park JH, Kim DS, et al. Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies. Endocrinology and Metabolism. 2018;33(4):473–84.
Xu J, Ding K, Mu L, Huang J, Ye F, Peng Y, et al. Hashimoto’s Thyroiditis: A “Double-Edged Sword” in Thyroid Carcinoma. Front Endocrinol (Lausanne). 2022;24;13.
Hu X, Wang X, Liang Y, Chen X, Zhou S, Fei W, et al. Cancer Risk in Hashimoto’s Thyroiditis: a Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2022;12:13.
Lai X, Xia Y, Zhang B, Li J, Jiang Y. A meta-analysis of Hashimoto’s thyroiditis and papillary thyroid carcinoma risk. Oncotarget. 2017;8(37):62414–24.
